OIG Nixes Pharmaceutical Cost-Sharing Subsidy Program Under AKS | Baker Ober Health Law
To embed, copy and paste the code into your website or blog: In Advisory Opinion No. 20-05, posted September 23, 2020, OIG was unwilling to approve a pharmaceutical companys proposed cost-sharing subsidy program for beneficiaries seeking to use its expensive new drug for treatment of a rare cardiovascular disease. While OIG stated it was not in a position to reach a definitive conclusion regarding whether a violation of the federal Anti-Kickback Statute (AKS) existed, OIG was unwilling to issue...
United States Baker Ober Health Law Subsidy Program Subsidy Program May Decrease Fair Competition Subsidy Program Could Potentially Impact Clinical Decision Baker Ober Health
Source: jdsupra.com